Mark Danta
Impact in
- Hepatology top 0.5%
- Hepatitis C virus research
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Epidemiology top 2%
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- HIV, Drug Use, Sexual Risk
Papers in
- Hepatology 41
- Hepatitis C virus research 31
- Liver Disease and Transplantation 12
- Hepatocellular Carcinoma Treatment and Prognosis 6
- Epidemiology 38
- Liver Disease Diagnosis and Treatment 25
- Hepatitis B Virus Studies 14
- Co-authors
- Gail Matthews (7 shared papers)Geoffrey Dusheiko (9 shared papers)Gregory J. Dore (14 shared papers)Behzad Hajarizadeh (9 shared papers)Janaki Amin (4 shared papers)Matthew Law (4 shared papers)Maria Prins (2 shared papers)Sanjay Bhagani (5 shared papers)
- Journals
- Journal of Hepatology (6 papers)Hepatology (6 papers)Alimentary Pharmacology & Therapeutics (4 papers)Frontiers in Immunology (3 papers)AIDS (3 papers)
- Partner nations
- AustraliaUnited KingdomUnited States
In The Last Decade
Mark Danta
63 papers receiving 1.8k citations
Mark Danta's Hit Papers
Peers
Comparison fields: 5 of 99
- Hepatology 1.3k
- Epidemiology 1.2k
- Infectious Diseases 460
- Virology 100
- Emergency Medicine 92
Countries citing papers authored by Mark Danta
This map shows the geographic impact of Mark Danta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Danta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Danta more than expected).
Fields of papers citing papers by Mark Danta
This network shows the impact of papers produced by Mark Danta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Danta. The network helps show where Mark Danta may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Danta, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 66 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression Hit paper breakdown → | 2017 | 344 |
| 2 | 2007 | 313 | |
| 3 | 2010 | 170 | |
| 4 | 2020 | 87 | |
| 5 | 2008 | 84 | |
| 6 | 2012 | 82 | |
| 7 | 2022 | 59 | |
| 8 | 2012 | 50 | |
| 9 | 2011 | 47 | |
| 10 | 2007 | 35 | |
| 11 | 2018 | 31 | |
| 12 | 2021 | 30 | |
| 13 | 2016 | 29 | |
| 14 | 2008 | 26 | |
| 15 | 2014 | 26 | |
| 16 | 2019 | 24 | |
| 17 | 2017 | 23 | |
| 18 | 2020 | 22 | |
| 19 | 2005 | 21 | |
| 20 | 2002 | 21 |
About Mark Danta
Mark Danta is a scholar working on Hepatology, Epidemiology, Infectious Diseases, Emergency Medicine and Immunology, having authored 66 papers that have together received 1.8k indexed citations. Recurring topics across this work include Hepatitis C virus research (31 papers), Liver Disease Diagnosis and Treatment (25 papers), Hepatitis B Virus Studies (14 papers), Liver Disease and Transplantation (12 papers), HIV-related health complications and treatments (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers), HIV Research and Treatment (5 papers) and HIV/AIDS drug development and treatment (5 papers). The work is most often cited by research in Hepatology (1.3k citations), Epidemiology (1.2k citations), Infectious Diseases (460 citations), Virology (100 citations) and Emergency Medicine (92 citations). Mark Danta has collaborated with scholars based in Australia, United Kingdom and United States. Frequent co-authors include Gail Matthews, Geoffrey Dusheiko, Gregory J. Dore, Behzad Hajarizadeh, Janaki Amin, Matthew Law, Maria Prins, Sanjay Bhagani, Reem Waziry and Oliver G. Pybus. Their work appears in journals such as Journal of Hepatology, Hepatology, Alimentary Pharmacology & Therapeutics, Frontiers in Immunology and AIDS.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.